{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-25-000052","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.134349+00:00","generated_at":"2026-05-23T22:09:57.202815+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"confidence":"high","headline":"Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M","bullets":["Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.","Net loss of $14.8M ($0.47 diluted loss per share) vs prior-year net income of $15.6M including $21M non-cash debt derivative gain.","Adjusted EBITDA $5.7M, down from $6.4M YoY; gross profit fell to $9.8M from $11.9M.","Sold unused high-speed isolator filler for $17M; $7M received at closing, remainder over 18 months. Signed multiple new development agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-25-000052","json":"https://secwatch.observer/filing/0001005286-25-000052.json","markdown":"https://secwatch.observer/filing/0001005286-25-000052.md","text":"https://secwatch.observer/filing/0001005286-25-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000052/0001005286-25-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000052/lndc-20250403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:09:57.202815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}